|
|---|
|
|
|
|
|
p********e
发帖数: 1960 | | f**********g
发帖数: 2252 | 2 18%!
Pharmasset announces expansion of ELECTRON trial in HCV
25 minutes ago - DTM via Comtex
DatamonitorPharmasset, Inc. has announced the addition of three treatment
cohorts to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase
inhibitor, for the treatment of chronic hepatitis C, or HCV.
The rapid and consistent antiviral effects and high barrier to resistance
demonstrated with PSI-7977 to date provide the rationale for additional
exploratory regimens in this setting. This amendment will add one arm
exploring 12 weeks of PSI-7977 monotherapy (without peginterferon and
ribavirin) and two arms of interferon-sparing therapy: one for 8 weeks of
PSI-7977 plus peginterferon and ribavirin (Peg-IFN/RBV) in patients with HCV
genotype 2 (GT2) or 3 (GT3) and one for 12 weeks of PSI-7977 plus Peg-IFN/
RBV in patients with HCV genotype 1 (GT1) prior null responses.
Pharmasset anticipates reporting results from the first four arms of the
trial (n=40) during the second half of 2011.
The ELECTRON trial is an exploratory study of PSI-7977 for the treatment of
chronic HCV infection. Part 1 of the trial is evaluating 12-week regimens of
PSI-7977 400mg QD in combination with ribavirin (RBV) only, and in separate
arms with abbreviated durations of Peg-IFN for 4, 8, or 12 weeks in
treatment-naive patients with HCV GT2 or GT3. The primary endpoint of the
trial is the safety and tolerability of PSI-7977 400mg QD and RBV for 12
weeks, administered with or without Peg-IFN.
"The combination data reported at EASL demonstrated that SVRs were
achievable with two oral DAAs in the absence of peginterferon and ribavirin,
" stated Bill Symonds, PharmD, Pharmasset's Senior vice president of
Clinical Pharmacology and Translational Medicine, "We continue to explore
the potential for removing peginterferon and ribavirin from the HCV
treatment regimen. Given the encouraging data we are seeing in ELECTRON, we
have decided to expand the study to investigate PSI-7977 monotherapy, as
well as shorter treatment regimens based on the promising data we reported
at EASL from PROTON."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon | l***y
发帖数: 582 | | w***y
发帖数: 2537 | | p********e
发帖数: 1960 | 5
He mentioned VRUS when it was like 60 in March...when VRTX was around 45
He bought VRTX...I think
【在 w***y 的大作中提到】
: 它什么时候推荐过？
| f**********g
发帖数: 2252 | 6 U are right.
http://www.mitbbs.com/clubarticle_t/pennystock/31529259.html
【在 p********e 的大作中提到】
:
: He mentioned VRUS when it was like 60 in March...when VRTX was around 45
: He bought VRTX...I think
| w***y
发帖数: 2537 | | J********e
发帖数: 341 | 8 INHX是用与VRUS同一个原理来做药的。
好像最近谁推荐过。
【在 p********e 的大作中提到】
: Tai Niu le
| f**********g
发帖数: 2252 | 9 3x.
goldenpig
【在 J********e 的大作中提到】
: INHX是用与VRUS同一个原理来做药的。
: 好像最近谁推荐过。
| K********g
发帖数: 9389 | 10 下一个关注ACHN，枪在光头前面说。
【在 p********e 的大作中提到】
: Tai Niu le
| Y**U
发帖数: 911 | |
|
|
|
|
|
|
